Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder...Services Agreement • April 30th, 2021 • Monte Rosa Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
THIS SERVICES AGREEMENT (the “Agreement”) is made as of December 29, 2020, by and between Monte Rosa Therapeutics Ag (“Recipient”), and Monte Rosa Therapeutics, Inc. (“Service Company”) and shall be effective as of January 1, 2020.
Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder...Services Agreement • April 30th, 2021 • Monte Rosa Therapeutics, Inc. • Biological products, (no disgnostic substances)
THIS SERVICES AGREEMENT (this “Agreement”), effective as of 10 April, 2018 (the “Effective Date”), is by and between RIDGELINE THERAPEUTICS GMBH, a Basel Switzerland corporation (“Ridgeline”), and MONTE ROSA THERAPEUTICS AG (in formation), a corporation to be registered in Switzerland (the “Company”).
Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder...Collaboration and Option Agreement • April 30th, 2021 • Monte Rosa Therapeutics, Inc. • Biological products, (no disgnostic substances) • England and Wales
THIS COLLABORATION AND OPTION AGREEMENT is entered into and made effective as of the 10th day of April, 2018 (the “Effective Date”), by and among:
Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder...Background Ip License Agreement • April 30th, 2021 • Monte Rosa Therapeutics, Inc. • Biological products, (no disgnostic substances) • England and Wales
NOW, THEREFORE, in consideration of the foregoing, the covenants and premises contained in this Agreement and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:
